Dermata Therapeutics Stock Technical Analysis

DRMA Stock  USD 1.24  0.02  1.64%   
Dermata Therapeutics's chart is summarized here using the indicators commonly applied to chart-based analysis. Higher-timeframe trends provide context for shorter-timeframe signals.
As of the 13th of May 2026, Dermata Therapeutics is trading near 1.24 per share. Technical analytics identify Standard Deviation of 9.07, variance of 82.28, and Mean Deviation of 5.12. The analytical framework assesses directional consistency across time frames. Momentum and trend indicators are compared to peer averages and recent trading history.

Dermata Therapeutics Momentum Analysis

Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Dermata, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to Dermata
  
Dermata Therapeutics' Momentum analyses are specifically helpful, as they help identify potential trend changes using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.

Analyst Consensus

Target PriceConsensus# of Analysts
4.0Buy1Odds
Historical and current analyst recommendations for Dermata Therapeutics are aggregated from multiple sources. Comparing current recommendations to historical patterns provides additional analytical context. Sell-side analysts covering Dermata typically assign buy, hold, or sell ratings alongside 12-month price targets. Ratings are usually accompanied by a target price comparing Dermata's fair price to its market value.
Dermata Analyst Advice Details
 Earnings Share
-8.16
 Return On Assets
-0.1%
 Return On Equity
-0.1%
Investors evaluate Dermata Therapeutics using market value and book value, each describing different facets of the business. Analytical frameworks help reconcile those views into a coherent picture.
It is useful to distinguish Dermata Therapeutics' value from its trading price, which are computed with different methods. For Dermata Therapeutics, key inputs include a P/B ratio of 0.81, and ROE of -0.12%.

What-If Analysis

What-if analysis for Dermata Therapeutics is essentially a historical sensitivity test that shows how changes in the investment horizon could have altered realized return, drawdown, and timing outcomes. The point is not to predict the future from one chart, but to understand how sensitive the trade has been to timing and holding assumptions.
0.00
02/12/2026
 
No Change 0.00  0.0 
In 2 months and 31 days
 
05/13/2026
0.00
Placing  0.00  into Dermata Therapeutics on February 12, 2026 with a hold through today would gain 0.00 in total return. In total, that is a 0.0% return on investment in Dermata Therapeutics in total across 90 days. Dermata Therapeutics has comparable peers such as Avenue Therapeutics, Psyence Biomedical, Virax Biolabs, Elevai Labs, GT Biopharma, Revelation Biosciences, and Artelo Biosciences. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializ... More

Upside and Downside Indicators for Dermata Therapeutics Summary

The momentum profile for Dermata Therapeutics describes how price movement distributes across upside and downside channels. Momentum distribution across the range reveals whether the current trend is accelerating or fading.

Market Risk Indicators for Dermata Therapeutics Snapshot

The risk context for Dermata Therapeutics is expressed through volatility and drawdown-related metrics. Drawdown depth and frequency distinguish between volatile-but-recoverable and structurally declining price behavior.
Mean reversion in Dermata Therapeutics' price occurs when temporary dislocations correct back toward its historical intrinsic value estimate. This tendency of Dermata Therapeutics' price to converge to an average value over time is called mean reversion.
Sentiment
Range
LowSentimentHigh
0.061.2310.24
Details
Intrinsic
Valuation
LowIntrinsicHigh
0.101.9110.92
Details
Naive
Forecast
LowNextHigh
0.021.2210.22
Details
Analyst
Consensus
LowTargetHigh
3.644.004.44
Details
Peer benchmarking frames Dermata Therapeutics's operating metrics and market pricing against comparable companies. Placing Dermata Therapeutics' results in peer context distinguishes company-specific performance from industry-wide trends.

Technical Indicators

Dermata Therapeutics Backtested Returns

Dermata Therapeutics continues to exhibit an extremely high risk exposure over the designated horizon. It has a Sharpe Ratio of 0.0252, evidencing risk-calibrated returns. We identified twenty-three technical indicators influencing the company's volatility profile. Please examine metrics such as standard deviation of 9.07, variance of 82.28, and mean deviation of 5.12 to validate volatility assumptions. On a scale of 0 to 100, Dermata Therapeutics holds a performance score of 2. The company has a market beta of 0.41, which conveys generally lower market sensitivity than the broad market. Dermata Therapeutics moves in the same direction as the market but with less intensity, offering a degree of cushion during selloffs.
Auto-correlation
    
  0.05  

Virtually no predictability

Serial correlation analysis for Dermata Therapeutics reveals virtually no predictability across the intervals from 12th of February 2026 to 29th of March 2026 and from 29th of March 2026 to 13th of May 2026. The degree of alignment between past and current intervals shapes expectations about Dermata Therapeutics's price persistence. At 0.05, only as little as 5.0% of current Dermata Therapeutics price movement aligns with historical price trajectory.
Correlation Coefficient0.05
Spearman Rank Test-0.08
Residual Average0.0
Price Variance0.0
Dermata Therapeutics technical stock analysis focuses on price and volume behavior. Common inputs include moving averages, RSI, and price-based signals.
Price movement for Dermata Therapeutics is analyzed through a technical framework. The focus is on trend development and recurring price patterns. More Info...

Technical Analysis

Indicator
Time Period
Execute Indicator
This analysis covers thirty-seven data points across the selected time horizon. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Dermata Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.

Technical Analysis Methodology & Indicators

Technical analysis of Dermata Therapeutics evaluates price structure, momentum, and volatility clustering. Price movements may be comparatively less responsive to macroeconomic volatility. Dermata Therapeutics has a market cap of 4.91 million, ROE of -1.94%.

Reported values for Dermata Therapeutics are derived from periodic company reporting and market reference feeds and standardized for analysis.

Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board

Technical Indicators

A technical review of Dermata Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. A disciplined technical workflow separates stronger setups from noisier price action.

May 13, 2026 Daily Trend Indicators

A technical review of Dermata Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. A disciplined technical workflow separates stronger setups from noisier price action.

Popular Tools for Dermata Stock analysis